About AbCellera Biologics Inc.
AbCellera is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women’s health, immunology, and oncology.
AbCellera Biologics Inc. (ABCL) Stock Score & Signals
AbCellera Biologics Inc. (ABCL) trades on NASDAQ. It operates in the Health Care sector, Biotechnology industry. Its current 2BB score is 35 out of 100.
2BB score and signals
AbCellera Biologics Inc.’s current 2BB score is 35 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 34 | Low |
| Momentum | 50 | Stable |
| Financial strength | 29 | Weak |
| Quality | 93 | Very Strong |
| Risk | 36 | Low (provisional) |
Company facts
| CEO | Carl Hansen |
| Headquarters | Vancouver, British Columbia, Canada |
| Founded | 2012 |
| Employees | 562 |
| 52-week range | $2.74 – $15.02 |
Recent earnings
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2027-02-22 | — | -0.1745 | — | $7.19M |
| 2026-11-09 | — | -0.1714 | — | $8.58M |